Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Where To Buy Lunesta In San Diego,.7093"

Looking for quality documents?
external link icon
Repligen Completes Acquisition of Novozymes Biopharma Sweden AB
external link icon
Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2008 Results
external link icon
Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich’s Ataxia
external link icon
Repligen Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement
Signs 15-year Strategic Collaboration and Exclusive License Agreement WALTHAM, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocessing market.
Through this agreement, Repligen will assume responsibility for the commercialization of Culpeo ® , as well as the development of future products and technologies in partnership with DRS Daylight Solutions (“Daylight”). Both companies will focus on expanding the portfolio of Quantum Cascade Laser mid-IR (QCL-IR) based solutions and integrating these solutions into Repligen Chromatography and Filtration systems to expand the companies’ presence in the fast-growing Process Analytics Technology (PAT) segment of the bioprocessing market. Daylight’s patented
external link icon
Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results Thursday, August 5th 10:00 a.m. EDT
external link icon
Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results Thursday, August 6th, 10:00 a.m. EDT
external link icon
Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results Thursday, June 11th, 10:00 a.m. EDT
external link icon
Repligen Announces Conference Call of Third Quarter Fiscal Year 2010 Results Thursday, February 4th, 10:00 a.m. EST
external link icon
Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results Thursday, February 5th, 10:00 a.m. EST
corporate icon
Charge Variant Analysis
Challenge: Charge heterogeneity in early development can affect efficacy and safety, but typical offline CEX or IEF methods are low throughput. Our Solution: ZipChip CE offers fast, high-resolution separation of charge variants to assess product consistency before scale-up.
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support